JP2020532300A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532300A5 JP2020532300A5 JP2020512512A JP2020512512A JP2020532300A5 JP 2020532300 A5 JP2020532300 A5 JP 2020532300A5 JP 2020512512 A JP2020512512 A JP 2020512512A JP 2020512512 A JP2020512512 A JP 2020512512A JP 2020532300 A5 JP2020532300 A5 JP 2020532300A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- item
- cells
- amino acid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 80
- 238000000034 method Methods 0.000 claims description 73
- 239000000203 mixture Substances 0.000 claims description 45
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 201000011510 cancer Diseases 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 38
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 30
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 30
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 29
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 29
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 28
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 21
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000002105 nanoparticle Substances 0.000 claims description 15
- 239000002671 adjuvant Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 210000004443 dendritic cell Anatomy 0.000 claims description 10
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 102000009016 Cholera Toxin Human genes 0.000 claims description 6
- 108010049048 Cholera Toxin Proteins 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 210000004748 cultured cell Anatomy 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 210000004180 plasmocyte Anatomy 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 4
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 3
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 3
- 229960004942 lenalidomide Drugs 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 2
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims description 2
- 102000006992 Interferon-alpha Human genes 0.000 claims description 2
- 108010047761 Interferon-alpha Proteins 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 102000043129 MHC class I family Human genes 0.000 claims description 2
- 108091054437 MHC class I family Proteins 0.000 claims description 2
- 206010060880 Monoclonal gammopathy Diseases 0.000 claims description 2
- 239000012648 POLY-ICLC Substances 0.000 claims description 2
- 208000004346 Smoldering Multiple Myeloma Diseases 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 102000002689 Toll-like receptor Human genes 0.000 claims description 2
- 108020000411 Toll-like receptor Proteins 0.000 claims description 2
- 102000008230 Toll-like receptor 3 Human genes 0.000 claims description 2
- 108010060885 Toll-like receptor 3 Proteins 0.000 claims description 2
- 229940037003 alum Drugs 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 229920002988 biodegradable polymer Polymers 0.000 claims description 2
- 239000004621 biodegradable polymer Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 229960001438 immunostimulant agent Drugs 0.000 claims description 2
- 239000003022 immunostimulating agent Substances 0.000 claims description 2
- 230000003308 immunostimulating effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims description 2
- 108700002563 poly ICLC Proteins 0.000 claims description 2
- 229940115270 poly iclc Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 2
- 229960000814 tetanus toxoid Drugs 0.000 claims description 2
- 239000003970 toll like receptor agonist Substances 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims 9
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- -1 immunoagonists Substances 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 21
- 239000000556 agonist Substances 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 4
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 3
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 3
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 3
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 2
- 108010075704 HLA-A Antigens Proteins 0.000 description 2
- 102000011786 HLA-A Antigens Human genes 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023192306A JP7644200B2 (ja) | 2017-09-01 | 2023-11-10 | Ｂｃｍａ抗原に特異的な免疫原性ペプチドおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553669P | 2017-09-01 | 2017-09-01 | |
| US62/553,669 | 2017-09-01 | ||
| PCT/US2018/049260 WO2019046818A1 (en) | 2017-09-01 | 2018-08-31 | SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192306A Division JP7644200B2 (ja) | 2017-09-01 | 2023-11-10 | Ｂｃｍａ抗原に特異的な免疫原性ペプチドおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532300A JP2020532300A (ja) | 2020-11-12 |
| JP2020532300A5 true JP2020532300A5 (enExample) | 2021-10-07 |
| JP7385556B2 JP7385556B2 (ja) | 2023-11-22 |
Family
ID=63678690
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020512512A Active JP7385556B2 (ja) | 2017-09-01 | 2018-08-31 | Ｂｃｍａ抗原に特異的な免疫原性ペプチドおよびその使用 |
| JP2023192306A Active JP7644200B2 (ja) | 2017-09-01 | 2023-11-10 | Ｂｃｍａ抗原に特異的な免疫原性ペプチドおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023192306A Active JP7644200B2 (ja) | 2017-09-01 | 2023-11-10 | Ｂｃｍａ抗原に特異的な免疫原性ペプチドおよびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11517591B2 (enExample) |
| EP (1) | EP3675897A1 (enExample) |
| JP (2) | JP7385556B2 (enExample) |
| KR (1) | KR102794702B1 (enExample) |
| CN (1) | CN111655280B (enExample) |
| AU (2) | AU2018326805B2 (enExample) |
| CA (1) | CA3070468A1 (enExample) |
| WO (1) | WO2019046818A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3555266B1 (en) * | 2016-12-13 | 2023-11-15 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same |
| CA3131138A1 (en) | 2019-03-06 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| CN115812077A (zh) | 2020-05-08 | 2023-03-17 | 高山免疫科学股份有限公司 | April和baff抑制性免疫调节蛋白及其使用方法 |
| US20240285740A1 (en) | 2021-05-12 | 2024-08-29 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
| US5804178A (en) | 1986-11-20 | 1998-09-08 | Massachusetts Institute Of Technology | Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
| US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
| US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| DK0585368T3 (da) | 1991-04-25 | 1998-03-16 | Univ Brown Res Found | Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter |
| CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| US5643786A (en) | 1995-01-27 | 1997-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for isolating dendritic cells |
| US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
| US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
| WO1997032603A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
| US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
| AU6685698A (en) | 1997-03-07 | 1998-09-22 | Sunol Molecular Corporation | Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor |
| US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
| ATE533784T1 (de) | 1997-10-02 | 2011-12-15 | Altor Bioscience Corp | Lösliche, einzelkettige proteine des t- zellrezeptors |
| JP2002507397A (ja) * | 1998-03-13 | 2002-03-12 | エピミューン，インコーポレイティド | Ｈｌａ結合ペプチド及びその使用 |
| US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6534633B1 (en) | 1998-10-21 | 2003-03-18 | Altor Bioscience Corporation | Polyspecific binding molecules and uses thereof |
| US20060067933A1 (en) | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
| EP1092439A1 (en) | 1999-10-13 | 2001-04-18 | Thorsten Dr. Ahlert | Activation of antigen-specific T cells by virus/antigen-treated dendritic cells |
| US7026443B1 (en) | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
| GB9930359D0 (en) | 1999-12-22 | 2000-02-09 | Glaxo Group Ltd | Novel polypeptides |
| PT1255558E (pt) | 2000-02-16 | 2006-11-30 | Genentech Inc | Anticorpos anti-april e células hibridoma |
| CN1312289A (zh) * | 2000-03-07 | 2001-09-12 | 上海博德基因开发有限公司 | 一种新的多肽——人促性腺释放激素23和编码这种多肽的多核苷酸 |
| CA2404945C (en) | 2000-04-27 | 2010-02-09 | Biogen, Inc. | Taci as an anti-tumor agent |
| CA2408617A1 (en) * | 2000-05-12 | 2001-11-22 | Amgen Inc. | Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
| US20020164346A1 (en) | 2001-02-14 | 2002-11-07 | Nicolette Charles A. | Altered peptide ligands |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| DK1436003T3 (da) | 2001-05-24 | 2010-03-15 | Zymogenetics Inc | TACI-immunoglobulin-fusionsproteiner |
| KR20040019105A (ko) | 2001-08-03 | 2004-03-04 | 제넨테크, 인크. | ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도 |
| WO2003020797A1 (en) | 2001-08-30 | 2003-03-13 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| US20040072246A1 (en) | 2001-09-11 | 2004-04-15 | Roland Martin | System and method for identifying t cell and other epitopes and the like |
| EP1670513B1 (en) | 2003-10-06 | 2013-01-23 | Cedars-Sinai Medical Center | Cox-2 inhibitors and dendritic cells for use in the treatment of cancer. |
| WO2005043155A1 (en) | 2003-10-21 | 2005-05-12 | Cedars-Sinai Medical Center | System and method for the treatment of cancer, including cancers of the central nervous system |
| WO2008143679A2 (en) * | 2006-06-01 | 2008-11-27 | Verenium Corporation | Nucleic acids and proteins and methods for making and using them |
| BRPI0817664A2 (pt) | 2007-10-12 | 2015-03-24 | Massachusetts Inst Technology | Nanopartículas, método para preparar nanopartículas e método para tratar terapeuticamente ou profilaticamente um indivíduo |
| US20110318380A1 (en) * | 2008-10-01 | 2011-12-29 | Dako Denmark A/S | MHC Multimers in Cancer Vaccines and Immune Monitoring |
| US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| EP2550529B1 (en) * | 2010-03-23 | 2021-11-17 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
| ES2835200T3 (es) | 2012-05-22 | 2021-06-22 | Us Health | Uso médico de células que comprenden receptores de células T anti-NY-ESO-1 |
| CN105377288B (zh) * | 2012-11-05 | 2019-11-15 | 达纳-法伯癌症研究所股份有限公司 | Xbp1、cd138和cs1肽的组合物制备药物的用途 |
| EP3747899A3 (en) | 2013-01-29 | 2021-02-24 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | High avidity binding molecules recognizing mage-a1 |
| BR112015021970A2 (pt) | 2013-03-14 | 2017-07-18 | Massachusetts Inst Technology | composições à base de nanopartículas |
| AU2014290288B2 (en) | 2013-07-15 | 2018-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human papillomavirus 16 E6 T cell receptors |
| US20150038682A1 (en) | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| WO2015059690A1 (en) * | 2013-10-24 | 2015-04-30 | Yeda Research And Development Co. Ltd. | Polynucleotides encoding brex system polypeptides and methods of using s ame |
| EP3131927B8 (en) | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| DK4023249T3 (da) | 2014-04-23 | 2025-01-13 | Modernatx Inc | Nukleinsyrevacciner |
| WO2016077525A2 (en) | 2014-11-14 | 2016-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human thyroglobulin t cell receptors |
| SG11201705264WA (en) | 2014-12-31 | 2017-07-28 | The Usa As Represented By The Secretary Detp Of Health And Human Services | Novel multivalent nanoparticle-based vaccines |
| US10858760B2 (en) | 2015-06-01 | 2020-12-08 | Medigene Immunotherapies Gmbh | T cell receptor library |
| US10228101B2 (en) | 2015-07-01 | 2019-03-12 | Mind Head Llc | LED light fixtures and LED lamps that are used to replace Par 36 halogen lamps and incandescent well lights |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| PT3337824T (pt) * | 2015-08-17 | 2020-09-10 | Janssen Pharmaceutica Nv | Anticorpos anti-bcma, moléculas de ligação a antigénio biespecíficas que ligam bcma e cd3, e suas utilizações |
| US10689450B2 (en) | 2016-04-01 | 2020-06-23 | Kite Pharma, Inc | BCMA binding molecules and methods of use thereof |
| DE102016115246C5 (de) | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| CA3044682A1 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| SG11201907580SA (en) | 2017-02-17 | 2019-09-27 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| CA3131138A1 (en) | 2019-03-06 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
-
2018
- 2018-08-31 WO PCT/US2018/049260 patent/WO2019046818A1/en not_active Ceased
- 2018-08-31 JP JP2020512512A patent/JP7385556B2/ja active Active
- 2018-08-31 EP EP18773913.1A patent/EP3675897A1/en active Pending
- 2018-08-31 US US16/641,722 patent/US11517591B2/en active Active
- 2018-08-31 CA CA3070468A patent/CA3070468A1/en active Pending
- 2018-08-31 KR KR1020207009561A patent/KR102794702B1/ko active Active
- 2018-08-31 AU AU2018326805A patent/AU2018326805B2/en active Active
- 2018-08-31 CN CN201880067594.4A patent/CN111655280B/zh active Active
-
2022
- 2022-10-31 US US18/051,492 patent/US20230248769A1/en active Pending
-
2023
- 2023-11-10 JP JP2023192306A patent/JP7644200B2/ja active Active
-
2024
- 2024-01-30 AU AU2024200560A patent/AU2024200560B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Palucka et al. | Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity | |
| US11096996B2 (en) | Cancer vaccines and vaccination methods | |
| Chiang et al. | A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside | |
| Tarhini et al. | Safety and immunogenicity of vaccination with MART-1 (26–35, 27L), gp100 (209–217, 210M), and tyrosinase (368–376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma | |
| Ashley et al. | Bone marrow–generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors | |
| Sommershof et al. | Chronic stress suppresses anti-tumor TCD8+ responses and tumor regression following cancer immunotherapy in a mouse model of melanoma | |
| JP5127224B2 (ja) | 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法 | |
| Berger et al. | Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma | |
| JP2005523277A (ja) | 癌の治療 | |
| Koski et al. | Reengineering dendritic cell‐based anti‐cancer vaccines | |
| Bianchi et al. | IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells | |
| US11883490B2 (en) | Induction of IL-12 using immunotherapy | |
| CN102281761A (zh) | 用于增强免疫应答的方法和含有mTOR抑制剂的组合物 | |
| JP2020532300A5 (enExample) | ||
| WO2007149518A2 (en) | Dna composition against tumor stromal antigen fap and methods of use thereof | |
| Nakai et al. | Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters | |
| Palucka et al. | Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma | |
| Szmania et al. | Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma | |
| Kim et al. | Immunotherapy of malignant melanoma with tumor lysate-pulsed autologous monocyte-derived dendritic cells | |
| US20120207775A1 (en) | Immunogenic Epitopes as Targets for Universal Cancer Vaccines | |
| JP6871432B2 (ja) | Ｐｌｋ１タンパク質に対する抗原に特異的なｔ細胞の免疫反応を誘導するｈｌａ−ａ２亜型に特異的なｐｌｋ１由来の抗原決定基 | |
| Stan et al. | DNA vaccines against cancer | |
| WO2018032501A1 (zh) | 一种新的肿瘤特异性多肽及其应用 | |
| Gustafson et al. | Therapeutic vaccines for malignant brain tumors | |
| Tigno-Aranjuez et al. | Dissociated induction of cytotoxicity and DTH by CFA and CpG |